Women Infertility - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 209 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Women Infertility - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2015', provides an overview of the Women Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Women Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Women Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Women Infertility Overview 10
Therapeutics Development 11
Pipeline Products for Women Infertility - Overview 11
Pipeline Products for Women Infertility - Comparative Analysis 12
Women Infertility - Therapeutics under Development by Companies 13
Women Infertility - Therapeutics under Investigation by Universities/Institutes 17
Women Infertility - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Women Infertility - Products under Development by Companies 22
Women Infertility - Products under Investigation by Universities/Institutes 27
Women Infertility - Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
Addex Therapeutics Ltd 29
Allergan Plc 30
AlphaMab Co., Ltd 31
APAvadis Biotechnologies Srl 32
ASKA Pharmaceutical Co., Ltd. 33
Astellas Pharma Inc. 34
Bayer AG 35
BIOCAD 36
Dong-A Socio Group 37
Dongkook Pharmaceutical Co., Ltd. 38
ElexoPharm GmbH 39
EndoCeutics, Inc. 40
Enteris BioPharma, Inc. 41
Euroscreen S.A. 42
Evotec AG 43
Ferring International Center S.A. 44
Finox AG 45
Forendo Pharma Limited 46
GlaxoSmithKline Plc 47
Glycotope GmbH 48
Kissei Pharmaceutical Co., Ltd. 49
Lipicard Technologies Limited 50
Merrion Pharmaceuticals Plc 51
Nippon Shinyaku Co., Ltd. 52
Nora Therapeutics, Inc. 53
ObsEva SA 54
Orphagen Pharmaceuticals, Inc. 55
Pantec Biosolutions AG 56
PharmaEssentia Corporation 57
Philogen S.p.A. 58
Reliance Life Sciences Pvt. Ltd. 59
Repros Therapeutics Inc. 60
SK Chemicals Co., Ltd. 61
Takeda Pharmaceutical Company Limited 62
TocopheRx, Inc. 63
Trophogen, Inc. 64
ValiRx Plc 65
Viteava Pharmaceuticals, Inc. 66
Zydus Cadila Healthcare Limited 67
Women Infertility - Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Combination Products 69
Assessment by Target 70
Assessment by Mechanism of Action 73
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
(anastrozole + levonorgestrel) - Drug Profile 80
acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 81
AKP-501 - Drug Profile 82
ASP-1707 - Drug Profile 83
barusiban - Drug Profile 84
BAY-1128688 - Drug Profile 85
bentamapimod - Drug Profile 86
Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile 87
Biosimilar 5 for Infertility - Drug Profile 88
Biosimilar 6 for Infertility - Drug Profile 89
Biosimilar 7 for Infertility and Oncology - Drug Profile 90
choriogonadotropin alfa - Drug Profile 91
DKF-301 - Drug Profile 92
DKF-304 - Drug Profile 93
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 94
Drugs for Endometriosis - Drug Profile 95
Drugs for Endometriosis and Uterine Fibroids - Drug Profile 96
elagolix sodium - Drug Profile 97
epelsiban besylate - Drug Profile 99
ESN-364 - Drug Profile 101
EVE-104 - Drug Profile 103
FE-999310 - Drug Profile 104
follitropin alfa - Drug Profile 105
follitropin alfa - Drug Profile 107
follitropin alfa - Drug Profile 108
follitropin alfa (recombinant) - Drug Profile 109
follitropin delta - Drug Profile 110
FP-5677 - Drug Profile 111
FSH-GEX - Drug Profile 112
kisspeptin-54 - Drug Profile 114
KLH-2109 - Drug Profile 115
KN-015 - Drug Profile 116
leuprolide acetate - Drug Profile 117
LM-001 - Drug Profile 118
LM-002 - Drug Profile 119
LT-6121 - Drug Profile 120
menotropins - Drug Profile 121
MER-104 - Drug Profile 122
MIA-602 - Drug Profile 124
Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile 126
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 127
NCE-403 - Drug Profile 128
NS-580 - Drug Profile 129
NT-100 - Drug Profile 130
OBE-001 - Drug Profile 131
PEG-FSH - Drug Profile 132
Peptides for Cancer and Endometriosis - Drug Profile 133
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 134
PGL-1001 - Drug Profile 135
PGL-2001 - Drug Profile 136
Progesterone Second Generation - Drug Profile 137
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 138
Recombinant Protein to Agonize Luteinizing Hormone for Infertility - Drug Profile 139
relugolix - Drug Profile 140
RTPR-013 - Drug Profile 141
S-hCG - Drug Profile 142
SKI-2670 - Drug Profile 143
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 144
Small Molecules for Female Infertility - Drug Profile 145
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 146
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 147
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 148
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 149
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 150
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 151
SR-16234 - Drug Profile 152
STI-2833 - Drug Profile 153
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 154
telapristone acetate - Drug Profile 155
Tetravil - Drug Profile 158
TOP-001 - Drug Profile 160
TOP-002 - Drug Profile 161
TR-4401 - Drug Profile 162
triptorelin - Drug Profile 163
VAL-201 - Drug Profile 164
vilaprisan - Drug Profile 166
VPE-001 - Drug Profile 167
VPEA-004 - Drug Profile 168
Women Infertility - Recent Pipeline Updates 169
Women Infertility - Dormant Projects 188
Women Infertility - Discontinued Products 192
Women Infertility - Product Development Milestones 194
Featured News & Press Releases 194
Appendix 202
Methodology 202
Coverage 202
Secondary Research 202
Primary Research 202
Expert Panel Validation 202
Contact Us 202
Disclaimer 203

List of Tables

Number of Products under Development for Women Infertility, H2 2015 17
Number of Products under Development for Women Infertility - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 20
Number of Products under Development by Companies, H2 2015 (Contd..1) 21
Number of Products under Development by Companies, H2 2015 (Contd..2) 22
Number of Products under Investigation by Universities/Institutes, H2 2015 23
Comparative Analysis by Late Stage Development, H2 2015 24
Comparative Analysis by Clinical Stage Development, H2 2015 25
Comparative Analysis by Early Stage Development, H2 2015 26
Comparative Analysis by Unknown Stage Development, H2 2015 27
Products under Development by Companies, H2 2015 28
Products under Development by Companies, H2 2015 (Contd..1) 29
Products under Development by Companies, H2 2015 (Contd..2) 30
Products under Development by Companies, H2 2015 (Contd..3) 31
Products under Development by Companies, H2 2015 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2015 33
Women Infertility - Pipeline by AbbVie Inc., H2 2015 34
Women Infertility - Pipeline by Addex Therapeutics Ltd, H2 2015 35
Women Infertility - Pipeline by Allergan Plc, H2 2015 36
Women Infertility - Pipeline by AlphaMab Co., Ltd, H2 2015 37
Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H2 2015 38
Women Infertility - Pipeline by ASKA Pharmaceutical Co., Ltd., H2 2015 39
Women Infertility - Pipeline by Astellas Pharma Inc., H2 2015 40
Women Infertility - Pipeline by Bayer AG, H2 2015 41
Women Infertility - Pipeline by BIOCAD, H2 2015 42
Women Infertility - Pipeline by Dong-A Socio Group, H2 2015 43
Women Infertility - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015 44
Women Infertility - Pipeline by ElexoPharm GmbH, H2 2015 45
Women Infertility - Pipeline by EndoCeutics, Inc., H2 2015 46
Women Infertility - Pipeline by Enteris BioPharma, Inc., H2 2015 47
Women Infertility - Pipeline by Euroscreen S.A., H2 2015 48
Women Infertility - Pipeline by Evotec AG, H2 2015 49
Women Infertility - Pipeline by Ferring International Center S.A., H2 2015 50
Women Infertility - Pipeline by Finox AG, H2 2015 51
Women Infertility - Pipeline by Forendo Pharma Limited, H2 2015 52
Women Infertility - Pipeline by GlaxoSmithKline Plc, H2 2015 53
Women Infertility - Pipeline by Glycotope GmbH, H2 2015 54
Women Infertility - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 55
Women Infertility - Pipeline by Lipicard Technologies Limited, H2 2015 56
Women Infertility - Pipeline by Merrion Pharmaceuticals Plc, H2 2015 57
Women Infertility - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 58
Women Infertility - Pipeline by Nora Therapeutics, Inc., H2 2015 59
Women Infertility - Pipeline by ObsEva SA, H2 2015 60
Women Infertility - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 61
Women Infertility - Pipeline by Pantec Biosolutions AG, H2 2015 62
Women Infertility - Pipeline by PharmaEssentia Corporation, H2 2015 63
Women Infertility - Pipeline by Philogen S.p.A., H2 2015 64
Women Infertility - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2015 65
Women Infertility - Pipeline by Repros Therapeutics Inc., H2 2015 66
Women Infertility - Pipeline by SK Chemicals Co., Ltd., H2 2015 67
Women Infertility - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 68
Women Infertility - Pipeline by TocopheRx, Inc., H2 2015 69
Women Infertility - Pipeline by Trophogen, Inc., H2 2015 70
Women Infertility - Pipeline by ValiRx Plc, H2 2015 71
Women Infertility - Pipeline by Viteava Pharmaceuticals, Inc., H2 2015 72
Women Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 73
Assessment by Monotherapy Products, H2 2015 74
Assessment by Combination Products, H2 2015 75
Number of Products by Stage and Target, H2 2015 77
Number of Products by Stage and Mechanism of Action, H2 2015 80
Number of Products by Stage and Route of Administration, H2 2015 83
Number of Products by Stage and Molecule Type, H2 2015 85
Women Infertility Therapeutics - Recent Pipeline Updates, H2 2015 175
Women Infertility - Dormant Projects, H2 2015 194
Women Infertility - Dormant Projects (Contd..1), H2 2015 195
Women Infertility - Dormant Projects (Contd..2), H2 2015 196
Women Infertility - Dormant Projects (Contd..3), H2 2015 197
Women Infertility - Discontinued Products, H2 2015 198
Women Infertility - Discontinued Products (Contd..1), H2 2015 199